Overview

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Status:
Active, not recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This research study is evaluating the experimental drug palbociclib in combination with another experimental drug PD-0325901 as a possible treatment for cancers with KRAS mutations, particularly for those which started in the lung.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Treatments:

Palbociclib